Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
13.44
-0.30 (-2.18%)
Aug 13, 2025, 4:00 PM - Market closed
Maze Therapeutics Employees
Maze Therapeutics had 125 employees as of December 31, 2024.
Employees
125
Change
n/a
Growth
n/a
Revenue / Employee
$20,000
Profits / Employee
-$590,384
Market Cap
589.36M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 125 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MAZE News
- 1 day ago - Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights - GlobeNewsWire
- 4 weeks ago - Maze Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones - GlobeNewsWire
- 3 months ago - Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference - GlobeNewsWire
- 4 months ago - Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights - GlobeNewsWire
- 6 months ago - Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease - GlobeNewsWire
- 6 months ago - U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs - Seeking Alpha